Nifty
Sensex
:
:
15763.05
52586.84
-15.40 (-0.10%)
-66.23 (-0.13%)

Pharmaceuticals & Drugs - Global

Rating :
45/99

BSE: 500257 | NSE: LUPIN

1107.40
30-Jul-2021
  • Open
  • High
  • Low
  • Previous Close
  •  1090.00
  •  1127.60
  •  1080.90
  •  1085.90
  • Volume
  • Traded Value (lacs)
  • 52 Week High
  • 52 Week Low
  •  1455348
  •  16074.13
  •  1267.65
  •  855.35

Stock Summary

  • Market Cap(Crs)
  • Stock P:E
  • Face Value
  • 50,260.56
  • 41.31
  • 2
  • Enterprise Value(Crs)
  • Dividend Yield
  • Price:Book Value
  • 53,301.08
  • 0.59%
  • 3.69

Shareholding Pattern

  • Promoter
  • Corporate
  • Public
  • 46.84%
  • 0.46%
  • 9.91%
  • FII
  • DII
  • Others
  • 18.6%
  • 21.82%
  • 2.37%

Chart

Price | P:E | P:BV | EV:EBITDA | MCap:Sales | EPS

Revenue CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • 7.91
  • -2.82
  • -3.27

EBITDA CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • 5.92
  • -10.59
  • -0.78

PAT CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • 3.52
  • -13.61
  • 26.10

P:E (Median)

  • 8 Years
  • 5 Years
  • 3 Years
  • 26.16
  • 23.10
  • -

P:BV (Average)

  • 8 Years
  • 5 Years
  • 3 Years
  • 4.93
  • 3.38
  • 3.03

EV:EBITDA (Average)

  • 8 Years
  • 5 Years
  • 3 Years
  • 16.17
  • 14.77
  • 15.38

Quarterly Results

Consolidated Figures in Rs. Crores /

Standalone
Description
Mar 21
Mar 20
Var%
Dec 20
Dec 19
Var%
Sep 20
Sep 19
Var%
Jun 20
Jun 19
Var%
Net Sales
3,783.10
3,845.74
-1.63%
4,017.36
3,769.27
6.58%
3,835.00
3,882.21
-1.22%
3,527.86
3,877.69
-9.02%
Expenses
3,075.55
3,320.42
-7.37%
3,238.62
3,340.17
-3.04%
3,253.83
3,241.64
0.38%
3,039.78
3,130.86
-2.91%
EBITDA
707.55
525.32
34.69%
778.74
429.10
81.48%
581.17
640.57
-9.27%
488.08
746.83
-34.65%
EBIDTM
18.70%
13.66%
19.38%
11.38%
15.15%
16.50%
13.84%
19.26%
Other Income
58.22
208.60
-72.09%
21.17
93.59
-77.38%
24.96
127.96
-80.49%
43.28
66.59
-35.01%
Interest
31.84
107.38
-70.35%
30.92
88.60
-65.10%
33.62
82.59
-59.29%
44.26
84.41
-47.57%
Depreciation
215.72
214.26
0.68%
244.32
253.23
-3.52%
212.73
252.57
-15.77%
214.64
250.16
-14.20%
PBT
518.21
495.37
4.61%
524.67
-107.82
-
359.78
-113.11
-
272.46
478.85
-43.10%
Tax
54.01
105.07
-48.60%
83.49
767.02
-89.12%
146.70
69.52
111.02%
164.32
215.50
-23.75%
PAT
464.20
390.30
18.93%
441.18
-874.84
-
213.08
-182.63
-
108.14
263.35
-58.94%
PATM
12.27%
10.15%
10.98%
-23.21%
5.56%
-4.70%
3.07%
6.79%
EPS
10.15
8.60
18.02%
9.66
-18.44
-
4.66
-2.81
-
2.36
6.70
-64.78%

Annual Results

Consolidated Figures in Rs. Crores /

Standalone
Description
TTM
Mar 21
Mar 20
Mar 19
Mar 18
Mar 17
Mar 16
Mar 15
Mar 14
Mar 13
Mar 12
Net Sales
-
15,162.96
16,836.56
16,751.37
15,804.15
17,494.33
14,139.03
12,770.01
11,286.57
9,641.30
7,082.91
Net Sales Growth
-
-9.94%
0.51%
5.99%
-9.66%
23.73%
10.72%
13.14%
17.06%
36.12%
 
Cost Of Goods Sold
-
4,854.28
4,962.72
4,436.67
4,733.76
4,660.97
3,893.70
3,806.16
3,485.50
3,221.50
2,364.87
Gross Profit
-
10,308.68
11,873.84
12,314.70
11,070.39
12,833.36
10,245.33
8,963.85
7,801.07
6,419.80
4,718.04
GP Margin
-
67.99%
70.52%
73.51%
70.05%
73.36%
72.46%
70.19%
69.12%
66.59%
66.61%
Total Expenditure
-
12,596.08
14,362.21
14,082.44
12,656.64
13,001.19
10,453.68
9,150.42
8,283.78
7,371.41
5,638.20
Power & Fuel Cost
-
414.48
443.17
442.28
433.88
377.86
381.27
362.81
334.29
320.22
268.82
% Of Sales
-
2.73%
2.63%
2.64%
2.75%
2.16%
2.70%
2.84%
2.96%
3.32%
3.80%
Employee Cost
-
2,825.90
2,986.84
2,770.17
2,864.71
2,849.52
2,141.62
1,747.34
1,464.65
1,266.62
969.53
% Of Sales
-
18.64%
17.74%
16.54%
18.13%
16.29%
15.15%
13.68%
12.98%
13.14%
13.69%
Manufacturing Exp.
-
1,945.67
1,852.21
1,731.57
2,087.52
2,270.19
1,766.00
1,320.55
1,129.59
976.51
753.07
% Of Sales
-
12.83%
11.00%
10.34%
13.21%
12.98%
12.49%
10.34%
10.01%
10.13%
10.63%
General & Admin Exp.
-
1,218.42
1,456.46
3,302.60
1,219.96
1,509.56
1,195.98
806.87
810.53
692.06
471.23
% Of Sales
-
8.04%
8.65%
19.72%
7.72%
8.63%
8.46%
6.32%
7.18%
7.18%
6.65%
Selling & Distn. Exp.
-
1,026.40
1,080.45
1,206.60
1,150.61
1,049.48
870.29
835.48
775.26
709.62
647.88
% Of Sales
-
6.77%
6.42%
7.20%
7.28%
6.00%
6.16%
6.54%
6.87%
7.36%
9.15%
Miscellaneous Exp.
-
310.93
1,580.36
192.55
166.20
283.61
204.82
271.21
283.96
184.88
647.88
% Of Sales
-
2.05%
9.39%
1.15%
1.05%
1.62%
1.45%
2.12%
2.52%
1.92%
2.30%
EBITDA
-
2,566.88
2,474.35
2,668.93
3,147.51
4,493.14
3,685.35
3,619.59
3,002.79
2,269.89
1,444.71
EBITDA Margin
-
16.93%
14.70%
15.93%
19.92%
25.68%
26.07%
28.34%
26.60%
23.54%
20.40%
Other Income
-
136.29
483.76
333.01
150.35
106.51
185.19
239.75
116.48
27.85
14.35
Interest
-
140.64
362.98
302.49
204.35
152.53
59.47
9.81
26.65
40.95
35.47
Depreciation
-
887.41
970.22
846.05
1,085.87
912.23
487.13
434.70
260.97
332.19
227.52
PBT
-
1,675.12
1,624.91
1,853.40
2,007.64
3,534.89
3,323.94
3,414.83
2,831.65
1,924.60
1,196.07
Tax
-
448.52
1,146.56
901.69
288.46
978.51
1,059.34
970.40
962.15
584.16
308.56
Tax Rate
-
26.78%
131.36%
59.58%
53.10%
27.68%
31.87%
28.42%
33.98%
30.35%
25.80%
PAT
-
1,226.60
-273.72
611.73
247.74
2,549.21
2,255.84
2,403.24
1,836.37
1,314.16
867.65
PAT before Minority Interest
-
1,226.60
-273.72
611.73
254.83
2,556.38
2,264.60
2,444.43
1,869.50
1,340.44
887.51
Minority Interest
-
0.00
0.00
0.00
-7.09
-7.17
-8.76
-41.19
-33.13
-26.28
-19.86
PAT Margin
-
8.09%
-1.63%
3.65%
1.57%
14.57%
15.95%
18.82%
16.27%
13.63%
12.25%
PAT Growth
-
-
-
146.92%
-90.28%
13.00%
-6.13%
30.87%
39.74%
51.46%
 
EPS
-
27.02
-6.03
13.48
5.46
56.16
49.70
52.95
40.46
28.95
19.12

Results Balance Sheet

Consolidated Figures in Rs. Crores /

Standalone
Description
Mar 21
Mar 20
Mar 19
Mar 18
Mar 17
Mar 16
Mar 15
Mar 14
Mar 13
Mar 12
Shareholder's Funds
13,803.14
12,536.70
13,742.23
13,577.06
13,497.57
11,163.37
8,874.06
6,931.57
5,204.18
4,012.89
Share Capital
90.74
90.60
90.50
90.42
90.32
90.12
89.90
89.68
89.51
89.33
Total Reserves
13,522.87
12,231.40
13,433.31
13,275.26
13,233.50
10,958.87
8,728.15
6,815.66
5,107.79
3,920.76
Non-Current Liabilities
1,136.03
3,003.18
7,296.41
6,876.13
6,446.96
6,032.39
426.15
507.16
572.87
729.96
Secured Loans
0.33
0.70
358.82
448.03
217.15
5.55
12.50
24.42
37.95
27.76
Unsecured Loans
15.79
1,792.58
6,282.90
5,976.47
5,430.63
5,368.35
89.33
126.54
209.11
405.20
Long Term Provisions
329.49
296.29
370.79
356.85
308.73
190.00
162.03
132.49
112.45
77.02
Current Liabilities
8,436.09
9,225.20
6,129.87
5,095.55
6,120.59
5,061.17
3,729.23
2,629.55
3,006.92
3,120.30
Trade Payables
2,014.44
2,412.30
2,498.18
2,575.40
2,588.90
1,988.82
1,956.06
1,594.13
1,542.88
1,379.28
Other Current Liabilities
2,451.01
3,124.23
1,279.82
1,517.16
657.97
1,001.27
829.76
287.64
381.25
377.17
Short Term Borrowings
3,049.44
2,492.75
1,580.21
451.76
2,304.33
1,745.41
369.15
402.38
726.82
1,046.99
Short Term Provisions
921.20
1,195.92
771.66
551.23
569.39
325.67
574.26
345.40
355.97
316.86
Total Liabilities
23,430.23
24,809.54
27,215.37
25,588.82
26,099.64
22,289.01
13,053.54
10,135.22
8,843.42
7,935.44
Net Block
7,880.76
7,938.11
11,086.71
10,361.99
11,032.93
8,716.96
4,368.19
3,355.60
3,000.17
2,749.66
Gross Block
14,726.75
14,160.50
15,731.88
13,859.86
12,395.30
9,212.07
6,644.59
5,283.90
4,684.21
4,191.84
Accumulated Depreciation
6,845.99
6,222.39
4,645.17
3,497.87
1,362.37
495.11
2,276.40
1,928.30
1,684.04
1,442.18
Non Current Assets
9,443.86
9,396.33
13,361.79
13,379.28
14,146.71
12,401.61
5,221.19
4,034.77
3,700.29
3,593.12
Capital Work in Progress
1,066.26
939.62
1,639.71
2,598.20
2,133.06
2,702.40
551.87
285.90
310.70
434.84
Non Current Investment
78.07
36.07
185.63
26.71
22.00
14.33
2.51
2.06
2.06
2.80
Long Term Loans & Adv.
405.79
409.58
402.61
383.00
950.76
960.22
274.20
372.99
387.36
396.94
Other Non Current Assets
12.98
72.95
47.13
9.38
7.96
7.70
0.32
0.00
0.00
0.00
Current Assets
13,986.37
15,413.21
13,853.58
12,209.54
11,952.93
9,887.40
7,832.35
6,100.45
5,143.13
4,342.32
Current Investments
2,376.81
2,338.25
2,109.86
234.86
2,114.13
2.02
1,655.89
176.41
0.00
0.00
Inventories
4,092.01
3,456.87
3,836.77
3,662.49
3,642.28
3,273.65
2,503.56
2,129.45
1,948.93
1,732.67
Sundry Debtors
4,474.32
5,445.93
5,149.80
5,192.21
4,307.34
4,548.76
2,656.57
2,464.10
2,186.99
1,780.01
Cash & Bank
1,742.46
2,454.30
987.20
1,408.03
698.17
821.75
481.35
797.50
434.88
402.47
Other Current Assets
1,300.77
537.33
777.47
621.30
1,191.01
1,241.22
534.98
532.99
572.33
427.17
Short Term Loans & Adv.
743.88
1,180.53
992.48
1,090.65
657.58
761.78
294.91
275.15
339.67
306.12
Net Current Assets
5,550.28
6,188.01
7,723.71
7,113.99
5,832.34
4,826.23
4,103.12
3,470.90
2,136.21
1,222.02
Total Assets
23,430.23
24,809.54
27,215.37
25,588.82
26,099.64
22,289.01
13,053.54
10,135.22
8,843.42
7,935.44

Cash Flow

Consolidated Figures in Rs. Crores /

Standalone
Description
Mar 21
Mar 20
Mar 19
Mar 18
Mar 17
Mar 16
Mar 15
Mar 14
Mar 13
Mar 12
Cash From Operating Activity
1,821.76
1,468.84
1,665.97
1,751.19
4,113.51
-382.39
2,733.05
2,003.93
1,250.96
560.04
PBT
1,676.45
876.78
1,517.17
546.81
3,543.14
3,328.84
3,414.83
2,831.65
1,924.60
1,196.07
Adjustment
1,053.31
1,574.29
1,588.41
2,782.23
1,214.74
585.35
356.73
410.50
419.58
258.51
Changes in Working Capital
-192.49
-471.02
-500.19
-1,019.43
504.62
-3,126.44
-94.91
-466.31
-549.35
-580.65
Cash after chg. in Working capital
2,537.27
1,980.05
2,605.39
2,309.61
5,262.50
787.75
3,676.65
2,775.84
1,794.83
873.93
Interest Paid
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Tax Paid
-715.51
-511.21
-939.42
-558.42
-1,148.99
-1,170.14
-943.60
-771.91
-543.87
-313.89
Other Direct Exp. Paid
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Extra & Other Items
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Cash From Investing Activity
-1,239.58
1,106.99
-3,282.47
469.87
-2,527.44
-6,961.71
-1,054.51
-858.54
-521.86
-741.25
Net Fixed Assets
-693.00
-481.49
-462.56
-1,394.31
-876.24
480.96
-416.45
-309.36
-324.79
-389.71
Net Investments
-2,106.15
-67.96
-2,025.62
1,551.07
-3,173.10
-296.59
-2,280.57
-475.62
-0.75
-6.41
Others
1,559.57
1,656.44
-794.29
313.11
1,521.90
-7,146.08
1,642.51
-73.56
-196.32
-345.13
Cash from Financing Activity
-1,885.27
-890.58
744.13
-1,492.10
433.18
5,836.38
-196.89
-857.11
-662.82
108.86
Net Cash Inflow / Outflow
-1,303.09
1,685.25
-872.37
728.96
2,019.25
-1,507.72
1,481.65
288.28
66.28
-72.35
Opening Cash & Equivalents
2,229.31
544.06
1,416.43
687.47
780.22
2,095.06
606.62
310.93
244.65
295.88
Closing Cash & Equivalent
926.22
2,229.31
544.06
1,416.43
2,799.47
780.22
2,108.43
606.62
310.93
244.65

Financial Ratios

Consolidated /

Standalone
Description
Mar 21
Mar 20
Mar 19
Mar 18
Mar 17
Mar 16
Mar 15
Mar 14
Mar 13
Mar 12
Book Value (Rs.)
300.06
272.01
298.87
295.64
295.04
245.21
196.17
154.00
116.13
89.78
ROA
5.09%
-1.05%
2.32%
0.99%
10.57%
12.82%
21.08%
19.70%
15.98%
12.40%
ROE
9.46%
-2.12%
4.55%
1.91%
20.98%
22.80%
31.09%
30.89%
29.12%
24.35%
ROCE
9.70%
6.02%
8.45%
3.54%
18.53%
24.38%
40.30%
40.97%
32.70%
24.40%
Fixed Asset Turnover
1.96
2.10
1.93
2.07
1.63
1.80
2.16
2.28
2.19
1.99
Receivable days
64.06
61.62
66.11
63.76
91.82
92.24
72.65
74.67
74.61
77.76
Inventory Days
48.75
42.41
47.94
49.03
71.70
73.96
65.73
65.48
69.24
75.12
Payable days
62.54
65.89
68.49
68.56
60.60
63.20
64.43
63.78
63.76
64.11
Cash Conversion Cycle
50.26
38.14
45.56
44.23
102.92
103.00
73.94
76.37
80.10
88.76
Total Debt/Equity
0.35
0.51
0.63
0.53
0.60
0.65
0.06
0.09
0.22
0.41
Interest Cover
12.91
3.40
6.00
3.66
24.18
56.89
349.10
107.25
48.00
34.72

News Update:


  • Lupin’s arm to acquire 100% stake in Southern Cross Pharma Pty
    30th Jul 2021, 11:19 AM

    As a part of the transaction, Generic Health will gain access to over 60 registered products having sales of over Australian dollar 30 million

    Read More
  • Lupin launches Tavaborole Topical Solution
    13th Jul 2021, 15:22 PM

    The product will be manufactured at Lupin’s facility in Pithampur, India

    Read More
  • Lupin’s arm gets USFDA’s nod for supplemental new drug application for SOLOSEC
    2nd Jul 2021, 10:33 AM

    Trichomoniasis vaginalis is the most common non-viral, curable sexually transmitted infection in the U.S

    Read More
  • Lupin gets USFDA’s tentative approval for Dolutegravir, Lamivudine and TLD Tablets
    30th Jun 2021, 10:00 AM

    This product would be manufactured at Lupin’s Nagpur facility in India

    Read More
  • Lupin launches Emtricitabine, Tenofovir Disoproxil Fumarate Tablets in US
    26th Jun 2021, 09:06 AM

    Emtricitabine and Tenofovir Disoproxil Fumarate Tablets had estimated annual sales of $2.1 billion in the U.S

    Read More
  • Lupin gets USFDA approval for Sevelamer Hydrochloride Tablets
    17th Jun 2021, 14:43 PM

    The product will be manufactured at Lupin’s facility in Nagpur, India

    Read More
  • Lupin’s arm gets approval to market Luforbec
    14th Jun 2021, 15:41 PM

    Luforbec 100/6 µg pMDI is indicated for regular treatment of asthma and for the symptomatic treatment of patients with severe chronic obstructive pulmonary disease

    Read More
  • Lupin gets warning letter from USFDA for Somerset facility
    14th Jun 2021, 09:13 AM

    The USFDA had inspected the Lupin Somerset site from September 10, 2020 to November 5, 2020

    Read More
  • Lupin’s CSR arm donates Oxygen generation plants in Maharashtra, MP and Gujarat
    12th Jun 2021, 09:24 AM

    The company is in discussions with other states to assist them in their fight against the pandemic through similar initiatives

    Read More
  • Lupin gets USFDA’s nod for Emtricitabine, Tenofovir Disoproxil Fumarate Tablets
    7th Jun 2021, 16:10 PM

    The product will be manufactured at Lupin’s facility in Nagpur, India

    Read More
  • Lupin launches Digital Asthma Educator platform
    7th Jun 2021, 11:26 AM

    The platform guides asthma patients on the correct technique of using inhalers

    Read More
  • Lupin launches authorized generic version of Brovana in United States
    4th Jun 2021, 09:38 AM

    Arformoterol Tartrate Inhalation Solution is indicated for the long-term, twice daily maintenance treatment of bronchoconstriction in patients with COPD

    Read More
  • Lupin gets nod to enter into digital healthcare space
    3rd Jun 2021, 10:56 AM

    The Company recently incorporated a new entity in the name of Lupin Digital Health, as a wholly owned subsidiary, which will undertake this

    Read More
  • Lupin gets USFDA acceptance for Pegfilgrastim Biosimilar application
    2nd Jun 2021, 14:55 PM

    Pegfilgrastim has estimated annual sales of $ 3.66 billion in the U.S. (IQVIA MAT December 2020)

    Read More
  • Lupin gets $50 million from Boehringer Ingelheim for achievement of key milestones
    27th May 2021, 12:04 PM

    In 2019, Lupin and Boehringer Ingelheim had inked a licensing, development and commercialisation agreement for Lupin's novel oncology compound

    Read More
  • Lupin reports 18% rise in Q4 consolidated net profit
    14th May 2021, 09:36 AM

    The company has reported a standalone net profit of Rs 316.36 crore for the quarter ended March 31, 2021

    Read More
  • Lupin enters into voluntary licensing agreement with Lilly
    10th May 2021, 13:21 PM

    The timely restricted emergency use of Baricitinib will be an important life-saving treatment for patients with moderate to severe symptoms of COVID-19

    Read More
  • Lupin recalls 17,814 bottles of Cefprozil in US market
    26th Apr 2021, 10:00 AM

    According to the USFDA, the company is recalling the affected lot for being ‘Superpotent’

    Read More

Source: www.accordfintech.com | DISCLAIMER: Information is provided " as is" and solely for informational purposes, not for trading purposes or advice, and may be delayed.